Brief: Actinium Presents New Data Demonstrating Effective Lymphodepletion With Lutetium-177 For Car-T
25/06/2019 13:49
June 25 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PRESENTS NEW DATA DEMONSTRATING EFFECTIVE
LYMPHODEPLETION WITH LUTETIUM-177 FOR CAR-T AT THE 2019 SOCIETY
OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING
* ACTINIUM PHARMACEUTICALS INC - ACTINIUM'S - ACT OR
ADOPTIVE CELL
THERAPY PROGRAM NOW CAPABLE OF USING MULTIPLE WARHEADS
* ACTINIUM PHARMACEUTICALS INC - EFFECTIVE LYMPHODEPLETION
WITH
RADIOISOTOPE LU-177 OR LUTETIUM-177 WAS ACHIEVED WITH ITS ACT
PROGRAM
Source text for Eikon: ID:nPn6x6mn5a
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities